JP2016503399A - 組合せ - Google Patents

組合せ Download PDF

Info

Publication number
JP2016503399A
JP2016503399A JP2015539782A JP2015539782A JP2016503399A JP 2016503399 A JP2016503399 A JP 2016503399A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2016503399 A JP2016503399 A JP 2016503399A
Authority
JP
Japan
Prior art keywords
combination
cancer
compound
administered
cetuximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503399A5 (enExample
Inventor
フース，アクセル
グレショック，ジョエル
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016503399A publication Critical patent/JP2016503399A/ja
Publication of JP2016503399A5 publication Critical patent/JP2016503399A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015539782A 2012-10-25 2013-10-24 組合せ Pending JP2016503399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718430P 2012-10-25 2012-10-25
US61/718,430 2012-10-25
PCT/US2013/066564 WO2014066606A2 (en) 2012-10-25 2013-10-24 Combination

Publications (2)

Publication Number Publication Date
JP2016503399A true JP2016503399A (ja) 2016-02-04
JP2016503399A5 JP2016503399A5 (enExample) 2016-12-08

Family

ID=50545472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539782A Pending JP2016503399A (ja) 2012-10-25 2013-10-24 組合せ

Country Status (11)

Country Link
US (1) US20150273057A1 (enExample)
EP (1) EP2911673A4 (enExample)
JP (1) JP2016503399A (enExample)
KR (1) KR20150070393A (enExample)
CN (1) CN104812391A (enExample)
AU (1) AU2013334599B2 (enExample)
BR (1) BR112015009134A2 (enExample)
CA (1) CA2889530A1 (enExample)
MX (1) MX2015005307A (enExample)
RU (1) RU2015119218A (enExample)
WO (1) WO2014066606A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525948A (ja) * 2016-06-03 2019-09-12 ジョルダーノ キャポニグロー 薬学的組み合わせ

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181243B2 (en) * 2013-12-03 2015-11-10 Hangzhou Pushai Pharmaceutical Technology Co. Ltd. Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof
BR112016011222A2 (pt) * 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
CA2944085C (en) * 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
WO2017019279A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
CN108883182A (zh) * 2016-04-15 2018-11-23 伊莱利利公司 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
EP4259147A4 (en) * 2020-12-11 2024-10-23 Erasca, Inc. Combination therapies for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2011511074A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
JP2011519940A (ja) * 2008-05-06 2011-07-14 グラクソスミスクライン エルエルシー ベンゼンスルホンアミドチアゾール及びオキサゾール化合物
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008101840A1 (en) * 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
CN102859355B (zh) * 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
CN105640964A (zh) * 2010-04-21 2016-06-08 文蒂雷克斯药品公司 增强抗体依赖性细胞的细胞毒性的方法
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
MX352844B (es) * 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
MX375442B (es) * 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501631A (ja) * 2004-06-11 2008-01-24 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
JP2011511074A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用
JP2011519940A (ja) * 2008-05-06 2011-07-14 グラクソスミスクライン エルエルシー ベンゼンスルホンアミドチアゾール及びオキサゾール化合物
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Biomarkers and combination therapies", ANNALS OF ONCOLOGY, vol. Vol.23, Supplement5, JPN6017024730, January 2012 (2012-01-01), pages 3 - 2, ISSN: 0003735830 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525948A (ja) * 2016-06-03 2019-09-12 ジョルダーノ キャポニグロー 薬学的組み合わせ

Also Published As

Publication number Publication date
AU2013334599B2 (en) 2016-03-10
KR20150070393A (ko) 2015-06-24
WO2014066606A8 (en) 2015-06-04
CA2889530A1 (en) 2014-05-01
EP2911673A2 (en) 2015-09-02
EP2911673A4 (en) 2016-05-18
CN104812391A (zh) 2015-07-29
WO2014066606A2 (en) 2014-05-01
BR112015009134A2 (pt) 2017-07-04
AU2013334599A1 (en) 2015-04-30
WO2014066606A3 (en) 2014-07-10
RU2015119218A (ru) 2016-12-20
US20150273057A1 (en) 2015-10-01
MX2015005307A (es) 2015-07-17

Similar Documents

Publication Publication Date Title
US8952018B2 (en) Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
JP2017500307A (ja) がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
AU2013334599B2 (en) Combination
JP2019196391A (ja) 組み合わせ薬物療法
HK40081897A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40081897B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK1167287A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK1167287B (en) Combination comprising an mek inhibitor and a b-raf inhibitor

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180213